Papillary Glioneuronal Tumor: Unexplored Entity

Lavrnić, Slobodan; Macvanski, Marija; Ristic-Balos, Dragana; Gavrilov, M; Damjanović, Dino; Gavrilović, Svetlana; Milićević, Miroslav; Skender-Gazibara, Milica; Stošić-Opinćal, Tatjana

doi:10.1055/s-0032-1313636

Cited by 10 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a single exception to the rule one case of PGNT recurred despite GTR and low proliferation [23]. Therefore, no certain correlation between outcome and the extent of the tumor resection or the proliferation index can be made, which might give the impression that genetic alterations of PGNT may be a key issue for our understanding [28].…”

Section: Discussionmentioning

confidence: 99%

An Individual Patient Data Meta-Analysis on Characteristics and Outcome of Patients with Papillary Glioneuronal Tumor, Rosette Glioneuronal Tumor with Neuropil-Like Islands and Rosette Forming Glioneuronal Tumor of the Fourth Ventricle

et al. 2014

View full text Add to dashboard Cite

Background and PurposeIn 2007, the WHO classification of brain tumors was extended by three new entities of glioneuronal tumors: papillary glioneuronal tumor (PGNT), rosette-forming glioneuronal tumor of the fourth ventricle (RGNT) and glioneuronal tumor with neuropil-like islands (GNTNI). Focusing on clinical characteristics and outcome, the authors performed a comprehensive individual patient data (IPD) meta-analysis of the cases reported in literature until December 2012.MethodsPubMed, Embase and Web of Science were searched for peer-reviewed articles reporting on PGNT, RGNT, and GNTNI using predefined keywords.Results95 publications reported on 182 patients (PGNT, 71; GNTNI, 26; RGNT, 85). Median age at diagnosis was 23 years (range 4–75) for PGNT, 27 years (range 6–79) for RGNT, and 40 years (range 2–65) for GNTNI. Ninety-seven percent of PGNT and 69% of GNTNI were located in the supratentorial region, 23% of GNTNI were in the spinal cord, and 80% of RGNT were localized in the posterior fossa. Complete resection was reported in 52 PGNT (73%), 36 RGNT (42%), and 7 GNTNI (27%) patients. Eight PGNT, 3 RGNT, and 12 GNTNI patients were treated with chemo- and/or radiotherapy as the primary postoperative treatment. Follow-up data were available for 132 cases. After a median follow-up time of 1.5 years (range 0.2–25) across all patients, 1.5-year progression-free survival rates were 52±12% for GNTNI, 86±5% for PGNT, and 100% for RGNT. The 1.5-year overall-survival were 95±5%, 98±2%, and 100%, respectively.ConclusionsThe clinical understanding of the three new entities of glioneuronal tumors, PGNT, RGNT and GNTNI, is currently emerging. The present meta-analysis will hopefully contribute to a delineation of their diagnostic, therapeutic, and prognostic profiles. However, the available data do not provide a solid basis to define the optimum treatment approach. Hence, a central register should be established.

show abstract

Section: Discussionmentioning

confidence: 99%

An Individual Patient Data Meta-Analysis on Characteristics and Outcome of Patients with Papillary Glioneuronal Tumor, Rosette Glioneuronal Tumor with Neuropil-Like Islands and Rosette Forming Glioneuronal Tumor of the Fourth Ventricle

et al. 2014

View full text Add to dashboard Cite

show abstract

“…To date, more than 60 cases have been recorded in the English literature to the best of the authors' knowledge. [3][4][5][6][7][8][9][10][11][12][13] However, the imaging features of PGNT have been only simply described in case reports or small series. Typically, this tumor presents a solid and cystic mass or a cyst with a mural nodule, and the solid part presents enhancement in postcontrast scans.…”

mentioning

confidence: 99%